Register
Login:
Share:
Email Facebook Twitter


London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis
Angus Energy in talks to buy 'transformational' gas asset in North England


Glaxosmithkline Share News (GSK)

Stock Market news at lse.co.uk - RSS News Feeds

Share News for Glaxosmithkline (GSK)


Share Price: 1,582.00Bid: 1,581.20Ask: 1,581.60Change: 0.00 (0.00%)No Movement on Glaxosmithkline
Spread: 0.40Spread as %: 0.03%Open: 1,577.60High: 1,586.80Low: 1,570.60Yesterday’s Close: 1,582.00




Glaxo reaches $150 mln settlement in nasal spray litigation

Wed, 19th Dec 2012 17:26

Dec 19 (Reuters) - British drugmaker GlaxoSmithKline Plc has reached a $1
50 million preliminary settlement with U.S. drug wholesalers who claimed the company improperly delayed entry to the market of generic alternatives to its nasal spray Flonase, according to court documents.

The settlement was reached with, among others, AmerisourceBergen Corp, Cardinal Health Inc, and McKesson Corp, who maintained that Glaxo had abused the citizen's petition process to maintain a market monopoly and overcharge for the spray by restricting access to less expensive generic versions.

The preliminary settlement was approved by the United States District Court for the Eastern District of Pennsylvania.





(Reporting By Toni Clarke; Editing by Gerald E. McCormick) Keywords: GLAXOSMITHKLINE SETTLEMENT

(toni.clarke@thomsonreuters.com)(617-856-4340)(Reuters Messaging: toni.clarke.reuters.com@reuters.net)

COPYRIGHT
Copyright Thomson Reuters 2012. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.






UPDATE 1-GSK brings back bonuses for some sales reps

(Adds background on bribery scandals and fines)May 23 (Reuters) - British drugmaker GlaxoSmithKline said on Thursday it will reintroduce incentive pay
[23 May '19 18:07]

GSK to change incentives for sales representatives

May 23 (Reuters) - British drugmaker GlaxoSmithKline said on Thursday it will change incentives for sales representatives in some countries as it look
[23 May '19 15:21]

UPDATE 1-Amgen to buy Copenhagen-based Nuevolution for $167 mln

(Adds detail, background, shares)May 22 (Reuters) - Amgen, the world's largest biotechnology company, agreed on Wednesday to buy Scandinavian biopharm
[22 May '19 09:54]

UPDATE 2-Brexit worries hit domestic stocks but sterling slide lifts FTSE 100

* FTSE 100 up 0.1%, FTSE 250 down 0.7%* Exporters top boost to main index* Brexit-sensitive stocks slip* M&S slumps after discounted offering* IG gain
[22 May '19 09:33]

Trade rhetoric weighs on European shares

(For a live blog on European stocks, type LIVE/ in an Eikon news window)May 17 (Reuters) - European shares dropped on Friday after three days of gains
[17 May '19 08:03]

Ex-divs to take 23.6 points off FTSE 100 on May 16

MILAN, May 13 (Reuters) - The following FTSE 100 companies will go ex-dividend on Thursday, after which investors will no longer qualify for the lates
[13 May '19 09:55]

UK regulator investigates China's state broadcaster for airing TV confession

LONDON, May 8 (Reuters) - Britain's broadcasting watchdog has launched a formal investigation into whether a confession made by a British man and aire
[8 May '19 15:14]

UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S.

May 4 (Reuters) - British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc i
[4 May '19 17:24]



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.